BNP Paribas Financial Markets
ORMP icon

BNP Paribas Financial Markets’s Oramed Pharmaceuticals ORMP Stock Holding History

BNP Paribas Financial Markets’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47.7K Buy
+9,918
New +$39.5K ﹤0.01% 4905
2024
Q1 		– Sell
-2
Closed -$5 – 4177
2023
Q4 		$5 Sell
2
-11
-85% -$23 ﹤0.01% 3990
2023
Q3 		$34 Buy
+13
New +$41 ﹤0.01% 3875
2023
Q1 		– Sell
-130
Closed -$1.56K – 4004
2022
Q4 		$1.56K Buy
130
+1
+0.8% +$8 ﹤0.01% 3760
2022
Q3 		$836 Sell
129
-68,221
-100% -$552K ﹤0.01% 4451
2022
Q2 		$313K Sell
68,350
-6,691
-9% -$35.8K ﹤0.01% 2898
2022
Q1 		$649K Buy
75,041
+54,775
+270% +$561K ﹤0.01% 2606
2021
Q4 		$289K Buy
20,266
+14,874
+276% +$311K ﹤0.01% 3258
2021
Q3 		$119K Buy
5,392
+4,363
+424% +$74.3K ﹤0.01% 3216
2021
Q2 		$13.8K Buy
+1,029
New +$11.8K ﹤0.01% 3641

Other funds holding ORMP

Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $163M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BNP Paribas Financial Markets's ORMP Position: Q2 2026 in Review

BNP Paribas Financial Markets opened a new position in Oramed Pharmaceuticals (ORMP) in Q2 2026: 9,918 shares worth $47.7K. The stake represents ﹤0.01% of the portfolio and ranks #4905 among its holdings. This is a return to the name: BNP Paribas Financial Markets previously reported a position in ORMP as recently as Q4 2023.

BNP Paribas Financial Markets first reported a position in ORMP in Q2 2021 and has held it in 10 quarters since. The position peaked at $649K in Q1 2022. 84 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

  • BNP Paribas Financial Markets held 9,918 shares of Oramed Pharmaceuticals worth $47.7K as of Q2 2026.
  • Oramed Pharmaceuticals was a new BNP Paribas Financial Markets position in Q2 2026.
  • Oramed Pharmaceuticals made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4905 holding.
  • BNP Paribas Financial Markets first reported a position in Oramed Pharmaceuticals in Q2 2021 and has held it in 10 quarters since.
  • BNP Paribas Financial Markets's Oramed Pharmaceuticals position peaked at $649K in Q1 2022.
  • 84 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.